Loading data for LRMR — first visit, this takes a few seconds.
Larimar Therapeutics Inc. (LRMR)
NasdaqGM: LRMR
· Real-Time Price · USD
4.05
-0.12 (-2.88%)
At close: Aug 27, 2026, 8:00 PM
4.05
-0.01%
After-hours: 4:55 PM
The price, the headline numbers and the latest news, in one place.
Larimar Therapeutics Inc. (LRMR) Stock Price, Analysis & Data
-2.88% (1D)
No data available
| Bid | 2.95 |
| Market Cap | 420.73M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -172.6M |
| 0.75 | |
| -2.01 | |
| n/a | |
| -3.82 | |
| P/B (ttm) | 3.32 |
| P/S (ttm) | n/a |
| Earnings Date | Nov 5, 2026 |
| Ask | 5.29 |
| Volume | 672,764 |
| Avg. Volume (20D) | 1,960,793 |
| Open | 4.16 |
| Previous Close | 4.17 |
| Day's Range | 4.02 - 4.16 |
| 52-Week Range | 2.71 - 6.42 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About LRMR
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania....
Industry Biotechnology
Sector Healthcare
IPO Date Jun 19, 2014
Employees 71
Stock Exchange NasdaqGM
Ticker Symbol LRMR
Website https://www.larimartx.com
Financial Performance
In 2025, Larimar Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -165.67M, an increase of 105.54%.
Financial StatementsEarnings Surprise
Larimar Therapeutics has released their quarterly earnings on Aug 4, 2026:
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -0.3 exceeds estimates by 0.08, with 26.83% YoY growth.
Larimar Therapeutics Inc. is scheduled to release its earnings on Nov 5, 2026, before market opens.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2